


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9685533/publications.pdf Version: 2024-02-01

version. 2024-02-01



KE XII

#	Article	IF	CITATIONS
1	<scp>PDCD10</scp> promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating <scp>EMT</scp> pathway. Cancer Medicine, 2023, 12, 1673-1684.	2.8	5
2	Potential Alterations of Functional Connectivity Analysis in the Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Neural Plasticity, 2021, 2021, 1-9.	2.2	5
3	Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice. Cancer Investigation, 2021, 39, 571-581.	1.3	7
4	Depression Induced by CUMS Leads to Bladder Cancer Development and Local Tumor Immunosuppression in Mice. Journal of Oncology, 2021, 2021, 1-10.	1.3	6
5	Increased Risk of Recurrence of Non-Muscle Invasive Bladder Cancer Associated With Psychological Distress: A Prospective Cohort Study. Psychiatry Investigation, 2021, 18, 718-727.	1.6	0
6	Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. Molecular Pharmaceutics, 2021, 18, 4015-4028.	4.6	24
7	The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. Frontiers in Oncology, 2021, 11, 752860.	2.8	6
8	Tumor- and Osteoblast-Derived Periostin in Prostate Cancer bone Metastases. Frontiers in Oncology, 2021, 11, 795712.	2.8	1
9	Chronic Unpredictable Mild Stress Accelerates the Growth of Bladder Cancer in a Xenograft Mouse Model. Psychology Research and Behavior Management, 2020, Volume 13, 1289-1297.	2.8	9
10	NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP. Chemotherapy, 2018, 63, 191-197.	1.6	3
11	A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy. Annals of Clinical and Laboratory Science, 2018, 48, 18-28.	0.2	1
12	Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma. Journal of International Medical Research, 2016, 44, 620-626.	1.0	4
13	Immobilization of ALAâ€Zn ^{II} Coordination Polymer Proâ€photosensitizers on Magnetite Colloidal Supraparticles for Target Photodynamic Therapy of Bladder Cancer. Small, 2015, 11, 6338-6346.	10.0	28
14	Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World Journal of Urology, 2015, 33, 1951-1957.	2.2	20
15	Retroperitoneal Laparoscopic Ureterolithotomy for Proximal Ureteral Calculi in Selected Patients. Scientific World Journal, The, 2014, 2014, 1-5.	2.1	4
16	Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?. Cancer Epidemiology, 2014, 38, 157-161.	1.9	13
17	The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 50.e1-50.e8.	1.6	58
18	Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 42.e13-42.e19.	1.6	46

Ke Xu

#	Article	IF	CITATIONS
19	Biopolymer-directed synthesis of high-surface-area magnetite colloidal nanocrystal clusters for dual drug delivery in prostate cancer. Journal of Materials Chemistry, 2012, 22, 19067.	6.7	24
20	Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Science, 2011, 9, 22.	1.7	37
21	Intraoperative frozen biopsy in wide surgical excision of Paget's disease of the scrotum. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 483-485.	1.6	9